CHUGAI PHARMACEUTICAL CO., LTD. Logo

CHUGAI PHARMACEUTICAL CO., LTD.

An R&D pharma leader in Japan creating innovative drugs via antibody engineering technology.

4519 | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
北区浮間五丁目5番1号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Chugai Pharmaceutical Co., Ltd. is a research and development-oriented pharmaceutical company and a member of the Roche Group. The company specializes in creating innovative prescription drugs to address unmet medical needs, leveraging its unique science and proprietary antibody engineering technologies. Chugai's growth strategy is driven by a shift towards discovery research and early clinical development, the application of digital technology (DX) across its value chain, and open innovation through external partnerships. It is a leading presence in the Japanese therapeutic antibody market.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-07-25 08:42
Interim Report
確認書
Japanese 9.6 KB
2025-07-25 08:40
Interim Report
半期報告書-第115期(2025/01/01-2025/12/31)
Japanese 298.8 KB
2025-04-22 09:07
Regulatory News Service
訂正臨時報告書
Japanese 39.1 KB
2025-03-28 06:43
Post-Annual General Meeting Information
臨時報告書
Japanese 27.8 KB
2025-03-27 08:12
Regulatory News Service
臨時報告書
Japanese 39.7 KB
2025-03-27 07:57
Governance Information
内部統制報告書-第114期(2024/01/01-2024/12/31)
Japanese 24.8 KB
2025-03-27 07:50
Registration Form
確認書
Japanese 9.6 KB
2025-03-27 07:48
Annual Report
有価証券報告書-第114期(2024/01/01-2024/12/31)
Japanese 3.3 MB
2024-07-26 08:02
Regulatory News Service
確認書
Japanese 9.6 KB
2024-07-26 08:01
Interim Report
半期報告書-第114期(2024/01/01-2024/12/31)
Japanese 330.6 KB
2024-07-26 07:35
Regulatory News Service
確認書
Japanese 9.6 KB
2024-07-26 07:30
Regulatory News Service
訂正有価証券報告書-第113期(2023/01/01-2023/12/31)
Japanese 1.8 MB
2024-04-25 08:09
Regulatory News Service
確認書
Japanese 9.6 KB
2024-04-25 08:07
Quarterly Report
四半期報告書-第114期第1四半期(2024/01/01-2024/03/31)
Japanese 272.0 KB
2024-04-24 08:21
Registration Form
確認書
Japanese 9.6 KB

Automate Your Workflow. Get a real-time feed of all CHUGAI PHARMACEUTICAL CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for CHUGAI PHARMACEUTICAL CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
SoftOx Solutions AS Logo
Develops non-toxic, AMR-safe antimicrobials for wound care, disinfection & airway infections.
Norway SOFTX
Solasia Pharma K.K. Logo
In-licenses and commercializes oncology treatments and supportive care products in Asia.
Japan 4597
Sopharma AD Logo
Develops, manufactures, and distributes pharmaceuticals and generics in Bulgaria and regional markets.
Bulgaria SFA
Spago Nanomedical AB Logo
Developing nanomedicines for precise cancer diagnosis and targeted radionuclide therapy.
Sweden SPAGO
Spexis AG Logo
Clinical-stage biopharma developing macrocyclic therapeutics for rare diseases and oncology.
Switzerland SPEX
Sprint Bioscience Logo
Develops & out-licenses preclinical oncology drugs for difficult-to-treat cancers.
Sweden SPRINT
STADA Arzneimittel AG Logo
A leading European manufacturer of generics, consumer healthcare, and specialty pharmaceuticals.
Germany SAZ
Stayble Therapeutics AB Logo
Develops an injectable drug for lumbar disc herniation pain as an alternative to surgery.
Sweden STABL
STCUBE Logo
Develops first-in-class immunotherapies targeting BTN1A1 for treatment-resistant cancers.
South Korea 052020
STELLA PHARMA CORPORATION Logo
Develops boron drugs for Boron Neutron Capture Therapy (BNCT), a targeted cancer radiation treatment.
Japan 4888

Talk to a Data Expert

Have a question? We'll get back to you promptly.